Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Eli Lilly and Company
University Health Network, Toronto
M.D. Anderson Cancer Center
Tempus AI
Actuate Therapeutics Inc.